24 March 2017
genedrive plc: Notice of Interim Results
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, will be announcing its interim results for the six months ended 31 December 2016 on Thursday, 30 March 2017.
For further details please contact:
David Budd: CEO
+44 (0)161 989 0245
Matthew Fowler: Finance Director
Peel Hunt LLP
+44 (0)207 418 8900
Consilium Strategic Communications
+44 (0)203 709 5700
Notes to editors
genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Genedrive® platform and MTB/RIF test have been launched in India and a Genedrive® HCV test has been successfully assessed by the Institut Pasteur, Paris.